Prevention of implantable-defibrillator shocks by treatment with sotalol

New England Journal of Medicine

Volumn 340, Issue 24, 1999, Pages 1855-1862

  Pacifico, Antonio ^a   Hohnloser, Stefan H ^b   Williams, John H ^c   Tao, Ben ^c   Saksena, Sanjeev ^d   Henry, Philip D ^a   Prystowsky, Eric N ^e  

^a Texas Arrhythmia Institute   (United States)

^b GOETHE UNIVERSITY   (Germany)

^c BAYER PHARMA AG   (Germany)

^d Eastern Heart Institute   (United States)

^e ST VINCENT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOTALOL;

ADULT; AGED; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATOR; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHOCK; TREATMENT OUTCOME; VERTIGO;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; CHEMOTHERAPY, ADJUVANT; DEFIBRILLATORS, IMPLANTABLE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; SOTALOL; STROKE VOLUME; SURVIVAL ANALYSIS; TACHYCARDIA;

EID: 0033578076     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199906173402402     Document Type: Article

References (26)

1. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933-40.
2. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-83.
3. Dorian P, Newman D. Effect of sotalol on ventricular fibrillation and defibrillation in humans. Am J Cardiol 1993;72:72A-79A.
4. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-8.
5. Siebels J, Cappato R, Ruppel R, Schneider MA, Kuck KH. ICD versus drugs in cardiac arrest survivors: preliminary results of the Cardiac Arrest Study Hamburg. Pacing Clin Electrophysiol 1993;16:552-8.
6. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993;329:452-8.
7. Reiffel JA, Hahn E, Hartz V, Reiter MJ. Sotalol for ventricular tachyarrhythmias: beta-blocking and class III contributions, and relative efficacy versus class I drugs after prior drug failure. Am J Cardiol 1997;79:1048-53.
8. The CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). Am J Cardiol 1993;72:280-7.
9. Hohnloser SH, Woosley RL. Sotalol. N Engl J Med 1994;331:31-8.
10. Zelen M. The randomization and stratification of patients to clinical trials. J Chronic Dis 1974;27:365-75.
11. SAS/STAT software: changes and enhancements through release 6.12. Cary, N.C.: SAS Institute, 1997:1-1167.
12. Benditt DG, Williams IH, Jin J, et al. Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation/atrial flutter. Am J Cardiol (in press).
13. Pacifico A, Johnson JW, Stanton MS, et al. Comparison of results in two implantable defibrillators. Am J Cardiol 1998;82:875-80.
14. Tokano T, Bach D, Chang J, et al. Effect of ventricular shock strength on cardiac hemodynamics. J Cardiovasc Electrophysiol 1998;9:791-7.
15. Joglar JA, Kessler DJ, Welch PJ, et al. Effects of repeated electrical defibrillations on cardiac troponin I levels. Am J Cardiol 1999;83:270-2.
16. de Vries JW, Bakker PF, Visser GH, Diephuis JC, van Huffelen AC. Changes in cerebral oxygen uptake and cerebral electrical activity during defibrillation threshold testing. Anesth Analg 1998;87:16-20.
17. Murkin JM, Baird DL, Martzke JS, Yee R. Cognitive dysfunction after ventricular fibrillation during implantable cardioverter/defibrillator procedures is related to duration of the reperfusion interval. Anesth Analg 1997; 84:1186-92.
18. Hegel MT, Griegel LE, Black C, Goulden L, Ozahowski T. Anxiety and depression in patients receiving implanted cardioverter-defibrillators: a longitudinal investigation. Int J Psychiatry Med 1997;27:57-69.
19. Bourke JP, Turkington D, Thomas G, McComb JM, Tynan M. Florid psychopathology in patients receiving shocks from implanted cardioverter-defibrillators. Heart 1997;78:581-3.
20. Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J Cardiol 1997;80:Suppl 9B:35J-39J.
21. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997;30:27-34.
22. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997;349:667-74. [Errata, Lancet 1997;349:1180, 1776.]
23. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997;349:675-82. [Erratum, Lancet 1997;349:1776.]
24. Böcker D, Bänsch D, Heinecke A, et al. Potential benefit from implantable cardioverter-defibrillator therapy in patients with and without heart failure. Circulation 1998;98:1636-43.
25. Pacifico A, Wheelan KR, Nasir N Jr, et al. Long-term follow-up of cardioverter-defibrillator implanted under conscious sedation in prepectoral subfascial position. Circulation 1997;95:946-50.
26. Domanski MJ, Zipes DP, Schron E. Treatment of sudden cardiac death: current understandings from randomized trials and future research directions. Circulation 1997;95:2694-9.